Globe Life Inc. · NYSE (us_market)
Financial Services · Insurance - Life · United States
Globe Life Inc., through its subsidiaries, provides various life and supplemental health insurance products to lower middle- and middle-income families in the United States. It operates in three segments: Life Insurance, Supplemental Health Insurance, and Investments. The company offers whole, term, and other life insurance products, as well as life insurance for children; Medicare supplement and limited-benefit supplemental health insurance products, such as accident, cancer, critical illness, heart, intensive care, and other health products; and final expense, accidental death, mortgage protection, and hospital insurance products. It sells its products through direct-to-consumer channels, exclusive independent agents, general agency independent agents, and brokers. The company was formerly known as Torchmark Corporation and changed its name to Globe Life Inc. in August 2019. Globe Life Inc. was founded in 1900 and is headquartered in McKinney, Texas.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2024-02-28$128.40 RISE2024-06-14$77.89 PEAK2024-09-04$105.55 189d | -39.3% 107d | 2024-04-11 $49.17 | 2024-09-04 $105.55 | 89Quality on Sale | 71Deep Value | +35.5% 82d | +114.7% Held 146d |
DROP2024-02-28$128.40 RISE2024-04-11$49.17 PEAK2024-05-08$89.49 70d | -61.7% 43d | 2024-04-11 $49.17 | 2024-05-08 $89.49 | 89Quality on Sale | 75Deep Value | +82.0% 27d | +82.0% Held 27d |
DROP2022-02-09$106.24 RISE2022-06-13$88.38 PEAK2022-08-18$105.02 190d | -16.8% 124d | Missed | Missed | — | — | +18.8% 66d | Missed |
DROP2020-03-02$96.14 RISE2020-07-09$70.19 PEAK2020-08-11$85.76 162d | -27.0% 129d | 2020-03-23 $58.15 | 2020-08-11 $85.76 | 84Deep Value | 68Deep Value | +22.2% 33d | +47.5% Held 141d |
DROP2020-02-20$111.16 RISE2020-05-13$66.55 PEAK2020-06-08$87.24 109d | -40.1% 83d | 2020-03-12 $63.78 | 2020-06-08 $87.24 | 81Deep Value | 68Deep Value | +31.1% 26d | +36.8% Held 88d |
DROP2020-02-20$111.16 RISE2020-03-23$58.15 PEAK2020-06-08$87.24 109d | -47.7% 32d | 2020-03-12 $63.78 | 2020-06-08 $87.24 | 81Deep Value | 68Deep Value | +50.0% 77d | +36.8% Duplicate trade Held 88d |
Earlier in 2026, Globe Life Inc. reported first-quarter net operating income rising 11.7% year over year, with higher life and health premiums and investment income, but earnings slightly missed estimates due to elevated expenses, while management raised full-year 2026 net operating income guidance to US$15.40–US$15.90 per diluted share. A major analyst subsequently downgraded the stock’s rating even as they acknowledged the improved earnings outlook, underscoring a cautious stance toward...
Earlier in 2026, Globe Life Inc. reported first-quarter net operating income rising 11.7% year over year, with higher life and health premiums and investment income, but earnings slightly missed estimates due to elevated expenses, while management raised full-year 2026 net operating income guidance to US$15.40–US$15.90 per diluted share. A major analyst subsequently downgraded the stock’s rating even as they acknowledged the improved earnings outlook, underscoring a cautious stance toward...
Morgan Stanley stock is in a buy zone of a base. A biometric identity name hit a new high after rebounding following a sell signal.
Morgan Stanley stock is in a buy zone of a base. A biometric identity name hit a new high after rebounding following a sell signal.
Globe Life (GL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Globe Life (GL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Morgan Stanley analyst Bob Huang maintains Globe Life (NYSE:GL) with a Overweight and raises the price target from $176 to $181.
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from scaled industry giants and can be disrupted by new innovative players vying for a slice of the pie.
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from scaled industry giants and can be disrupted by new innovative players vying for a slice of the pie.
Accident and health insurers are gaining from underwriting growth, technology adoption and rising demand for supplemental coverage.
Accident and health insurers are gaining from underwriting growth, technology adoption and rising demand for supplemental coverage.
Accident and Health Insurance stocks like AFL, UNM, GL, TRUP and EIG are set to gain from rising underwriting exposure and accelerated digitalization. However, pricing pressure is a concern given rising medical costs and inflation.
Accident and Health Insurance stocks like AFL, UNM, GL, TRUP and EIG are set to gain from rising underwriting exposure and accelerated digitalization. However, pricing pressure is a concern given rising medical costs and inflation.
UNM eyes premium and earnings growth in 2026, backed by strong sales trends, persistency and expanding product lines.
UNM eyes premium and earnings growth in 2026, backed by strong sales trends, persistency and expanding product lines.
Globe Life (GL) has drawn fresh attention after recent share price moves, with the stock closing at US$155.04. For investors, the key question is how that level lines up with its fundamentals. See our latest analysis for Globe Life. Recent moves around US$155.04 sit within a broader upswing, with a 30-day share price return of 4.0% and a 1-year total shareholder return of 28.1%, suggesting momentum has been building over both shorter and longer horizons. If Globe Life’s recent run has you...
Globe Life (GL) has drawn fresh attention after recent share price moves, with the stock closing at US$155.04. For investors, the key question is how that level lines up with its fundamentals. See our latest analysis for Globe Life. Recent moves around US$155.04 sit within a broader upswing, with a 30-day share price return of 4.0% and a 1-year total shareholder return of 28.1%, suggesting momentum has been building over both shorter and longer horizons. If Globe Life’s recent run has you...
The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.
The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.
Globe Life has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| GL | +0.34% | +4.72% | +9.57% | +25.74% |
| XLF | -0.65% | +0.55% | -5.82% | +1.22% |
| Alpha (stock − sector) | +1.00% | +4.18% | +15.39% | +24.52% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 3.66M | $509.18M | 0.02% | Added+15.3% | 2026-03-31 |
| Wellington | fundamental | 1.32M | $184.19M | 0.03% | Trimmed-16.3% | 2026-03-31 |
| FidelityFMR | fundamental | 1.05M | $146.12M | 0.01% | Added+44.1% | 2026-03-31 |
| TwoSigma | quant | 104.0K | $14.47M | 0.01% | Trimmed-43.8% | 2026-03-31 |
| Soros | macro | 59.7K | $8.31M | 0.09% | Trimmed-59.0% | 2026-03-31 |
| Citadel | multi-strat | 42.1K | $5.85M | 0.01% | Trimmed-63.8% | 2026-03-31 |
| Bridgewater | macro | 5.1K | $713.11K | 0.00% | Trimmed-92.4% | 2026-03-31 |
| DEShaw | quant | 3.0K | $421.69K | 0.00% | Trimmed-89.3% | 2026-03-31 |
| TRowePrice | fundamental | 222.7K | $31.00K | 0.00% | Added+82.9% | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-29 | MITCHELL ROBERT BRIAN | EVP, General Counsel and CRO | S Open-market sale | 100 | $155.57 | −$15.6K |
| 2026-05-29 | MITCHELL ROBERT BRIAN | EVP, General Counsel and CRO | S Open-market sale | 500 | $155.55 | −$77.8K |
| 2026-05-29 | MITCHELL ROBERT BRIAN | EVP, General Counsel and CRO | G Gift | 320 | — | +$0 |
| 2026-05-26 | SVOBODA FRANK M | Co-Chairman & CEO | M Option exercise(deriv) | 20,000 | — | +$0 |
| 2026-05-26 | SVOBODA FRANK M | Co-Chairman & CEO | S Open-market sale | 1,590 | $157.05 | −$249.7K |
| 2026-05-26 | SVOBODA FRANK M | Co-Chairman & CEO | S Open-market sale | 18,410 | $156.65 | −$2.88M |
| 2026-05-26 | SVOBODA FRANK M | Co-Chairman & CEO | M Option exercise | 20,000 | $100.74 | +$2.01M |
| 2026-05-26 | Kalmbach Thomas Peter | EVP & CFO | M Option exercise(deriv) | 10,000 | — | +$0 |
| 2026-05-26 | Kalmbach Thomas Peter | EVP & CFO | S Open-market sale | 7,936 | $156.59 | −$1.24M |
| 2026-05-26 | Kalmbach Thomas Peter | EVP & CFO | M Option exercise | 10,000 | $103.23 | +$1.03M |
| 2026-05-20 | Kalmbach Thomas Peter | EVP & CFO | M Option exercise(deriv) | 15,000 | — | +$0 |
| 2026-05-20 | Kalmbach Thomas Peter | EVP & CFO | S Open-market sale | 11,903 | $156.61 | −$1.86M |
| 2026-05-20 | Kalmbach Thomas Peter | EVP & CFO | M Option exercise | 15,000 | $103.23 | +$1.55M |
| 2026-05-12 | Kalmbach Thomas Peter | EVP & CFO | M Option exercise(deriv) | 20,000 | — | +$0 |
| 2026-05-12 | Kalmbach Thomas Peter | EVP & CFO | M Option exercise(deriv) | 15,000 | — | +$0 |
| 2026-05-12 | Kalmbach Thomas Peter | EVP & CFO | S Open-market sale | 1,761 | $154.16 | −$271.5K |
| 2026-05-12 | Kalmbach Thomas Peter | EVP & CFO | S Open-market sale | 13,876 | $153.59 | −$2.13M |
| 2026-05-12 | Kalmbach Thomas Peter | EVP & CFO | M Option exercise | 20,000 | $98.32 | +$1.97M |
| 2026-05-12 | Kalmbach Thomas Peter | EVP & CFO | S Open-market sale | 441 | $152.41 | −$67.2K |
| 2026-05-12 | Kalmbach Thomas Peter | EVP & CFO | S Open-market sale | 11,349 | $152.01 | −$1.73M |
| 2026-05-12 | Kalmbach Thomas Peter | EVP & CFO | M Option exercise | 15,000 | $98.32 | +$1.47M |
| 2026-05-07 | HENRIE MICHAEL SHANE | SVP & Chief Accounting Officer | M Option exercise(deriv) | 2,150 | — | +$0 |
| 2026-05-07 | HENRIE MICHAEL SHANE | SVP & Chief Accounting Officer | S Open-market sale | 505 | $155.78 | −$78.7K |
| 2026-05-07 | HENRIE MICHAEL SHANE | SVP & Chief Accounting Officer | S Open-market sale | 1,645 | $155.01 | −$255.0K |
| 2026-05-07 | HENRIE MICHAEL SHANE | SVP & Chief Accounting Officer | M Option exercise | 2,150 | $128.40 | +$276.1K |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-07-22upcoming | 3.68 | — | — |
| 2026-04-22 | 3.48 | 3.43 | -1.35% |
| 2026-02-04 | 3.44 | 3.39 | -1.32% |
| 2025-10-22 | 4.54 | 4.81 | +5.90% |
| 2025-07-23 | 3.25 | 3.27 | +0.76% |
| 2025-04-30 | 3.24 | 3.07 | -5.22% |
| 2025-02-05 | 3.12 | 3.14 | +0.66% |
| 2024-10-23 | 3.06 | 3.49 | +14.17% |
| 2024-07-24 | 2.91 | 2.97 | +2.15% |
| 2024-04-22 | 2.79 | 2.78 | -0.32% |
| 2024-02-07 | 2.69 | 2.88 | +7.14% |
| 2023-10-25 | 2.65 | 2.71 | +2.21% |
| 2023-07-26 | 2.58 | 2.61 | +1.35% |
| 2023-05-03 | 2.47 | 2.53 | +2.50% |
| 2023-02-01 | 2.17 | 2.24 | +3.20% |
| 2022-10-26 | 2.10 | 2.15 | +2.29% |